/UPDATE -- Seismic Pharmaceuticals/

In the news release, Seismic Pharmaceuticals Commences Global Phase 3 Trial of Istaroxime in Patients With Cardiogenic Shock, issued 09-Sep-2026 by Seismic Pharmaceuticals over PR Newswire, we are advised by the company that changes have been made. The complete, updated release follows,...